Lei Lei Wu

LifeMine Therapeutics raises $263M across Series D and E rounds to advance LIFE-001, a fungal-derived calcineurin inhibitor for transplant patients.

Intellia Therapeutics said it discovered a common link among the patients who faced the highest liver enzyme elevations after receiving its CRISPR gene editing treatment for ATTR amyloidosis.

Ex-BioNTech strategy chief Ryan Richardson launches Bios Life, a $25M-backed virtual cancer surveillance startup

Sionna Therapeutics’ shares fell more than 90% after reporting that its lead asset failed an early study and it is no longer advancing the experimental treatment going forward. Vertex's shares hit an all-time high at one point.

The FDA rejected ITM's radiopharmaceutical for neuroendocrine tumors because of manufacturing issues, delaying a potential challenger to Novartis’ Lutathera.

Vaderis Therapeutics raised a Series B to run a Phase 3 study of its AKT inhibitor engasertib in a rare blood disorder called hereditary hemorrhagic telangiectasia.

Epicrispr has raised a Series C round after sharing promising early data for EPI-321, a potential new way to treat facioscapulohumeral muscular dystrophy.

FDA approved Bristol Myers Squibb's iberdomide (Zenbexus) for relapsed/refractory multiple myeloma at $29,500/cycle, used with Darzalex and dexamethasone.

Capricor plans new HOPE-3 data and analyses to support a narrower Duchenne approval after an FDA adcomm rejected deramiocel.

EyePoint's vorolanib (Duravyu) failed Phase 3 LUGANO trial vs Regeneron/Bayer's Eylea, sending $EYPT shares down 70%. Second study LUCIA results expected Q4.